Compare KNSA & FORM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNSA | FORM |
|---|---|---|
| Founded | 2015 | 1993 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 6.4B |
| IPO Year | 2018 | 2002 |
| Metric | KNSA | FORM |
|---|---|---|
| Price | $95.50 | $82.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $111.57 | ★ $144.70 |
| AVG Volume (30 Days) | 869.4K | ★ 1.5M |
| Earning Date | 10-27-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 225.00 | N/A |
| EPS | 1.14 | ★ 1.89 |
| Revenue | ★ $677,564,000.00 | N/A |
| Revenue This Year | $54.80 | $33.84 |
| Revenue Next Year | $28.50 | $24.66 |
| P/E Ratio | $83.44 | ★ $43.97 |
| Revenue Growth | ★ 60.09 | N/A |
| 52 Week Low | $37.02 | $47.33 |
| 52 Week High | $99.31 | $160.27 |
| Indicator | KNSA | FORM |
|---|---|---|
| Relative Strength Index (RSI) | 58.64 | 40.70 |
| Support Level | $72.76 | $69.88 |
| Resistance Level | $98.90 | $103.93 |
| Average True Range (ATR) | 4.32 | 6.65 |
| MACD | -0.24 | 0.38 |
| Stochastic Oscillator | 68.28 | 43.94 |
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
FormFactor Inc is a provider of electrical and optical test and measurement technologies along the full semiconductor product lifecycle - from characterization, modeling, reliability, and design de-bug, to qualification and production test.. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.